T.R. Jeffry Evans - Concepedia

Author

T.R. Jeffry Evans

Beatson West of Scotland Cancer Centre ORCID

Also Known As

Anthony M. Joshua, Australian Pancreatic Cancer Genome Initiative (APGI), Evans, Thomas R, Evans,Thomas R, Kurt I Anderson, M Soukop, T Evans, T R Evans, T R J Evans, T R Jeffry Evans

192

Publications

13K

Citations

H-Index

Concepts

All Affiliations

Beatson West of Scotland Cancer Centre University of Glasgow St George's Hospital Institute of Cancer Research Cancer Research UK Scotland Institute

About

T.R. Jeffry Evans is an author at Beatson West of Scotland Cancer Centre specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	43	7.6K
2	Health Sciences	8	8	5.7K
3	Cell Biology	5	5	598
4	Biochemistry	4	4	121
5	Diabetes	1	1	20

T.R. Jeffry Evans

Publications

12.1K

Citations

H-Index

Page 1

	Year	Citations
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial Masatoshi Kudo, Richard S. Finn, Shukui Qin, The Lancet HepatologyMedicineRandomised Phase 3Clinical TrialsPathology	2018	5.3K
CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma Colin W. Steele, Saadia A. Karim, Joshua D.G. Leach, Cancer Cell	2016	819
Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer Jennifer P. Morton, Paul Timpson, Saadia A. Karim, Proceedings of the National Academy of Sciences	2009	673
SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma Andrew X. Zhu, Olivier Rosmorduc, T.R. Jeffry Evans, Journal of Clinical Oncology	2014	572
Targeting the <scp>LOX</scp> / <scp>hypoxia</scp> axis reverses many of the features that make pancreatic cancer deadly: inhibition of <scp>LOX</scp> abrogates metastasis and enhances drug efficacy Bryan W. Miller, Jennifer P. Morton, Mark Pinese, EMBO Molecular Medicine Tumor BiologyOncologyPancreatic CancerGastrointestinal OncologyMedicine	2015	259
A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors Nicola Steele, Jane A. Plumb, Laura Vidal, Clinical Cancer Research	2008	239
MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma Nigel B. Jamieson, Douglas C. Morran, Jennifer P. Morton, Clinical Cancer Research	2011	206
A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours David S. Boss, Hilary Glen, Jos H. Beijnen, British Journal of Cancer OncologyMedicineReceptor Tyrosine KinasePathologyAdvanced Solid Tumours	2012	185
A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma Kim Dalhoff, Janet Dancey, Lӕrke Boye Astrup, British Journal of Cancer	2003	168
LKB1 Haploinsufficiency Cooperates With Kras to Promote Pancreatic Cancer Through Suppression of p21-Dependent Growth Arrest Jennifer P. Morton, Nigel B. Jamieson, Saadia A. Karim, Gastroenterology	2010	159

Page 1